Updated analysis finds newer type of LDL-C reducing drugs still not cost-effective

Share this post

An updated analysis of the low-density lipoprotein cholesterol (LDL-C) lowering drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, finds they are not cost-effective at current prices and that even greater price reductions than previously estimated may be needed to meet cost-effectiveness thresholds.

This post was syndicated from Top Health News -- ScienceDaily. Click here to read the full text on the original website.


Share this post

Be the first to comment

Leave a Reply